RxDoctor Payments Data

Erin Jou, MD

Internal Medicine · New Hyde Park, NYNPI 1487941985

Payments from drug & device makers

$808,926in general payments, 2019–2025

Across 80 payments — averaging $10,112 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$807K
  • Novartis$2K
  • AbbVie$74
  • E.r. Squibb & Sons, L.L.C.$19
  • Adaptive Biotechnologies Corporation$13
$11,626in research payments, 2019–2025

Across 3 payments — averaging $3875.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$12K

What the payments were for

  • Consulting fees$2,10028%
  • Speaking & faculty fees$5,16070%
  • Food & beverage$1192%
  • Education$190%

General payments by program year

20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$808,926 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$160,384
Medicare patients
246
Services billed
1,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ImbruvicaIbrutinib41$648,136
VenclextaVenetoclax46$246,634
JakafiRuxolitinib Phosphate13$212,805
Darzalex FasproDaratumumab-Hyaluronidase-Fihj14$143,375
EliquisApixaban53$39,929
Posaconazole30$36,051
XareltoRivaroxaban24$18,009
Tenofovir Disoproxil Fumarate21$3,315
Hydroxyurea51$1,195
Levofloxacin30$234
Ondansetron Hcl14$227
Acyclovir26$226
Cyclobenzaprine Hcl17$77
Pantoprazole Sodium14$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVenclexta$74$246,63446 claims
PfizerEliquis$806,719$39,92953 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New Hyde Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →